KOSDAQMachinery455900

Angel Robotics

₩16,790▲ 6.54%2026-11-18 close
Market Cap
₩258.9B
Turnover
₩400M
Volume
20K
Shares out.
15.4M
PER
—
PBR
9.0×
EPS
-₩576
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Rebound, Losses Still Persist

Angel Robotics booked KRW 1.38 billion in sales in 3Q 2026, the highest of the last five quarters on a disclosed basis, while operating losses have run for five straight quarters and no profit turn appears in the filed numbers.

  1. 1

    Sales in 3Q 2026 were KRW 1.38 billion, the largest of the last five quarters and up 70.7% year on year.

  2. 2

    Annual operating losses were KRW 7.1 billion in 2022 and KRW 10.3 billion in 2025, with a 2025 operating margin of -221.4%.

  3. 3

    Total equity at end-2025 was KRW 32.6 billion against total liabilities of KRW 4.41 billion, a 2025 debt ratio of 13.5%.

  4. 4

    Medical wearable robots have carried reimbursement since December 2022, and Southeast Asian approvals are presented as the next growth axis.

  5. 5

    Because the last four quarters show net losses, the price-to-earnings ratio is not calculated, and the price-to-book ratio sits in a range with a large premium over net assets.

02

Business structure

Angel Robotics was founded in 2017 as a wearable robot company and listed on the KOSDAQ market on March 26, 2024. Its business spans four product lines.

The angel MEDI line, whose flagship is the Angel Legs M20, is used for gait training of patients with stroke, cerebral palsy and spinal cord injury, and in December 2022 it became the first wearable robot to receive Class 3 medical device certification and reimbursement under the national health insurance fee schedule.

The angel SUIT line includes the hip-assist Angel Suit H10, launched in June 2025, which extends the company's reach into recovery and daily-life return.

The angel GEAR line is an industrial upper-body assist device used for repetitive heavy-lifting work such as parcel loading and unloading, while the angel KIT brand supplies core robot components including actuators and inertial measurement modules.

As of 3Q 2024, product-level revenue mix was 82.68 percent angel MEDI, 2.25 percent angel GEAR and 8.6 percent wearable robot development services.

Customers include tertiary hospitals, the National Rehabilitation Center, regional medical institutions and welfare facilities, and in March 2026 the company said the two flagship products had been supplied to more than 126 institutions at home and abroad, totaling more than 165 units.

In 2025 the company exported angel MEDI units overseas, which was cited as a diversification of its revenue structure. Its overseas strategy is to secure approvals in three Southeast Asian countries, Vietnam, Thailand and Malaysia, and then expand into neighboring markets.

In domestic rehabilitation robotics, Cosmo Robotics, P&S Robotics and Hurotics are grouped as similar companies. In 2025 the company also signed a cooperation agreement with LIG Nex1 on defense-use wearable robots, extending its scope into defense and industrial safety.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩800M-₩2.8B−352.4%
2025Q4₩1.3B-₩2.8B−217.5%
2026Q1₩500M-₩2.7B−528.0%
2026Q2₩800M-₩3.5B−442.2%
2026Q3₩1.4B-₩2.7B−193.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.2B-₩7.1B-₩6.8B−325.1%—−183.2%
2023₩5.1B-₩6.5B-₩9.2B−126.2%−106.5%145.7%
2024₩4.2B-₩10.8B-₩10B−257.5%−24.8%8.8%
2025₩4.6B-₩10.3B-₩9.7B−221.4%−29.8%13.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual sales rose from KRW 2.18 billion in 2022 to KRW 5.15 billion in 2023, an increase of 135.6 percent, then fell 18.2 percent to KRW 4.21 billion in 2024 before rising 10.2 percent to KRW 4.64 billion in 2025. Among 2022 to 2025, 2023 was the largest year and 2022 the smallest.

Operating losses were KRW 7.1 billion in 2022, KRW 6.5 billion in 2023, KRW 10.8 billion in 2024 and KRW 10.3 billion in 2025, so the company recorded a loss in each year from 2022 through 2025. The loss narrowed in 2023 and 2025 and widened in 2024.

The operating margin moved from -325.1 percent in 2022 to -126.2 percent in 2023, worsened to -257.5 percent in 2024, and was -221.4 percent in 2025.

Net loss attributable to controlling shareholders was KRW 6.8 billion in 2022, KRW 9.24 billion in 2023, KRW 10 billion in 2024 and KRW 9.72 billion in 2025, and the net loss including non-controlling interests followed the same path.

Operating cash flow was KRW -5.76 billion in 2022, KRW -4.35 billion in 2023, KRW -7.23 billion in 2024 and KRW -7.22 billion in 2025, negative in all four years. The debt ratio was -183.2 percent in 2022, reflecting negative equity, then 145.7 percent in 2023, 8.8 percent in 2024 and 13.5 percent in 2025.

At end-2025 total equity was KRW 32.6 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 4.41 billion.

On a quarterly basis, sales bottomed at KRW 507 million in 1Q 2026, down 60.2 percent from the prior quarter, then rose to KRW 788 million in 2Q 2026 and KRW 1.38 billion in 3Q 2026, marking two consecutive quarters of growth.

Over the same span, the operating loss widened to KRW 3.49 billion in 2Q 2026 before narrowing to KRW 2.66 billion in 3Q 2026.

According to a Thebell report from April 2026, gross profit has stayed in the black since the listing, and the main drag on operating results is selling, general and administrative expense together with ongoing recurring R&D spending.

The net loss attributable to controlling shareholders over the last four quarters, from 4Q 2025 to 3Q 2026, totals KRW 8.8 billion.

05

Industry analysis

The end market for wearable rehabilitation robots moves with the pace of hospital adoption and the reimbursement schedule. The company describes medical robotics as a transition from limited test-stage adoption to actual clinical use, according to a Thebell report from April 2026.

Adoption of angel MEDI and angel SUIT has picked up, centered on tertiary hospitals, which is a positive signal. The company also acknowledges that the industry is still at an early stage and that profitability will take time.

The timing of reimbursement inclusion has not been set, and the company expects the reimbursement system could gradually widen as clinical data accumulates.

A 2024 brokerage analysis pointed to collective clinic closures at tertiary hospitals as a possible source of delay in wearable robot investment, which shows how sensitive hospital demand is to operating conditions.

In industrial use, stronger legal rules on industrial accidents and serious accidents have raised demand for preventing musculoskeletal injuries, as reflected in the company's 2024 investor materials. On competition, the company highlights that it holds CE, FDA and K-mark approvals, a point reported in 2024.

Compared with industrial robot peers in the same sector, the customer base and approval framework differ, which limits direct comparison. Overseas, Southeast Asia serves as a testbed for building references, so changes in the overseas revenue share are a key indicator for judging the industry trajectory.

06

Outlook

The company's medium-term direction can be grouped into three pillars: overseas expansion, certification, and a shift toward a data-driven platform. Angel Robotics launched the Angel Legs M20 in Malaysia in late January 2026, and in late April 2026 it obtained medical device approval in Malaysia for the Angel Suit H10.

In March 2026 the company said it would build on Southeast Asian approvals to accelerate expansion into markets such as Singapore and Indonesia, and broaden its global footprint through US FDA approval and European CE-MDR certification.

In June 2026 it was selected as the lead institution for a cross-ministry 'Brain to Robot' development project. The company presents a long-term goal of a virtuous cycle in which data gathered from wearable robots feeds back into product improvement.

In defense, the open question is whether the 2025 cooperation with LIG Nex1 translates into actual revenue. Growth in the medical segment depends on whether reimbursement is widened, and the schedule for inclusion has not yet been disclosed.

Overseas revenue so far reflects early references from the 2025 export of angel MEDI units, and the volume is described as small.

On a disclosed basis, 3Q 2026 sales rose to KRW 1.38 billion, but the operating loss of KRW 2.66 billion continues, so whether higher sales lead to a narrower loss is the next point to watch.

07

Valuation

PER
—
PBR
9.0×
ROE
-27.7%
EPS
-₩576
BPS
₩1,910
Dividend per share
₩0

For this company, comparisons based on net assets and sales carry more meaning than earnings-based measures. Because the last four quarters show net losses, the price-to-earnings ratio is not calculated.

The price-to-book ratio sits in a range with a large premium over net assets, measured against end-2025 equity attributable to controlling shareholders of KRW 32.6 billion. The dividend yield is below the industry average, so shareholder returns through dividends are limited under the current earnings structure.

Because sales are still small, multiples based on sales are open to a wider range of interpretation than profit-based measures. Annual sales were KRW 4.64 billion in 2025, and 3Q 2026 sales rose to the largest level of the last five quarters, so sales-based indicators are moving in a favorable direction.

While operating losses continue, profit-based indicators will depend on whether the loss narrows. This report does not include a view on the level or direction of the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Recovery in quarterly sales

After a low of KRW 507 million in 1Q 2026, sales rose to KRW 788 million in 2Q and KRW 1.38 billion in 3Q, two straight quarters of growth. 3Q 2026 sales were up 70.7 percent year on year and are the largest of the last five quarters on a disclosed basis. Annual sales also rose 10.2 percent to KRW 4.64 billion in 2025.

Reimbursement and clinical references

The company holds a product line that was the first wearable robot to receive reimbursement under the national health insurance schedule. It said in March 2026 that its two flagship products had been supplied to more than 126 institutions at home and abroad, totaling over 165 units. The company expects the reimbursement system could widen gradually as clinical data accumulates.

Expansion into Southeast Asia and defense

The company has obtained medical device approvals in three Southeast Asian countries, and in late April 2026 it secured approval in Malaysia for the Angel Suit H10. In 2025 it entered a cooperation arrangement with LIG Nex1 on defense wearable robots. If the overseas share of revenue grows, the company could reduce its dependence on domestic reimbursement.

09

Bear factors

Five straight quarters of operating losses

Operating losses have run for five straight quarters from 3Q 2025 through 3Q 2026, and widened to KRW 3.49 billion in 2Q 2026. The net loss attributable to controlling shareholders over the last four quarters totals KRW 8.8 billion. No quarter in the disclosed period shows a profit.

Burden of selling, G&A and R&D costs

According to an April 2026 Thebell report, gross profit stays positive, but selling, G&A and recurring R&D expenses keep the company in operating losses. The 2025 operating margin was -221.4 percent, which points to a fixed cost base large relative to sales. If costs rise alongside sales, the loss may narrow only slowly.

Small sales base and cash burn

Annual sales were KRW 4.64 billion in 2025, a small base, and fell 18.2 percent in 2024. Operating cash flow was negative in all four years from 2022 to 2025, at KRW -7.22 billion in 2025. The undetermined timing of reimbursement expansion adds to earnings volatility.

10

Risk factors

Earnings risk

Operating losses have been recorded in each year from 2022 through 2025, and all of the last five quarters were loss-making. If SG&A and R&D costs grow alongside sales, the timing of a profit turn could be pushed out. The 2026 annual report will show the full-year operating loss.

Regulatory and reimbursement risk

Medical revenue depends heavily on the reimbursement schedule and certification timelines. A 2024 brokerage analysis flagged that collective clinic closures at tertiary hospitals could delay wearable robot investment. Approvals differ by country, so the pace of overseas expansion could be slower than planned.

Management and registry changes

The registry record on a corporate information website lists the resignation and appointment of the chief executive on October 16, 2026, and the representative name changes from Cho Nam-min to Kong Kyung-chul. A leadership change can affect the continuity of medium-term strategy. This change should be cross-checked against official disclosures.

11

What to watch next

  1. Late March 2027

    The 2026 annual report is due around this time, and the key checks are full-year 2026 sales, operating loss and operating margin compared with -221.4 percent in 2025.

  2. May 15, 2027

    This is the filing deadline for the 1Q 2027 quarterly report, where the check is whether the sales recovery from KRW 507 million in 1Q 2026 continues and whether the operating loss narrows.

  3. Date not yet announced, after November 2026

    This covers new Southeast Asian approvals and exports, US FDA approval, European CE-MDR certification, and whether the defense cooperation becomes visible in revenue. Timing of reimbursement inclusion is also a point to watch.

12

Overall view

Angel Robotics has built its business around medical wearable robots, accumulating reimbursement status and clinical references. On a disclosed basis, annual sales rose from KRW 2.18 billion in 2022 to KRW 4.64 billion in 2025, and 3Q 2026 sales of KRW 1.38 billion were the largest of the last five quarters.

However, operating losses ran for four straight years from 2022 through 2025, all of the last five quarters were loss-making, and operating cash flow was negative in all four years.

On the balance sheet, end-2025 total equity of KRW 32.6 billion against total liabilities of KRW 4.41 billion points to a modest debt burden. Bullish factors include the sales recovery, expanding Southeast Asian approvals and the potential growth of defense cooperation.

Bearish factors include SG&A and R&D costs offsetting sales gains, a small revenue base and uncertainty over the timing of reimbursement expansion.

The next checkpoint is the 2026 annual report due around late March 2027, where full-year operating loss and operating margin versus -221.4 percent in 2025 will be the key figures. This summary is informational, is based on disclosures and press reports, and contains no investment opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. m.thebell.co.kr
  3. kr.investing.com
  4. m.news.nate.com
  5. mt.co.kr
  6. newspim.com
  7. angel-robotics.com
  8. inews24.com
  9. saramin.co.kr
  10. rapportian.com
  11. files-scs.pstatic.net
  12. jobkorea.co.kr
  13. hankyung.com
  14. youtube.com
  15. etoday.co.kr
  16. hankyung.com
  17. dailyinvest.kr
  18. linkonbiz.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis